文献速递血栓与止血

艾美赛珠单抗在伴或不伴抑制物的A型血友病患者中的1/2期研究长期安全性和疗效

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors.
PubMed 文献 · Blood Adv · 2017-09-27

该开放标签长期扩展研究纳入18例日本重型A型血友病患者中的16例,继续接受艾美赛珠单抗治疗最长33.3个月。长期治疗耐受良好,无血栓栓塞事件及中和性抗艾美赛珠单抗抗体发生,中位年出血率在队列1、2、3分别为1.4、0.2和0,较12周研究时的4.4、0和0维持低水平。

要点

  • 长期艾美赛珠单抗治疗耐受良好,无血栓栓塞事件和中和性抗体发生。
  • 队列1、2、3中位年出血率分别为1.4、0.2和0,与12周研究时4.4、0和0相比维持低水平。
  • 8例患者无出血事件(伴抑制物6例,不伴抑制物2例),剂量上调可进一步降低出血控制欠佳患者的年出血率。

核心结论

  • 长期艾美赛珠单抗治疗在伴或不伴FVIII抑制物的A型血友病患者中表现出良好的安全性特征和令人鼓舞的疗效。

研究设计与样本

  • 开放标签长期扩展研究,为既往报告的12周1期研究的延续,18例日本重型A型血友病患者中16例继续接受艾美赛珠单抗治疗最长33.3个月。
  • 1期试验中18例日本重型A型血友病患者每周一次皮下注射艾美赛珠单抗0.3、1或3 mg/kg(分别为队列1、2、3)。

主要发现

  • 长期艾美赛珠单抗治疗耐受良好,研究期间无血栓栓塞事件报告,无中和性抗艾美赛珠单抗抗体产生。
  • 艾美赛珠单抗血浆浓度呈剂量比例增加,活化部分凝血活酶时间保持缩短。
  • 队列1、2、3中位年出血率分别维持在1.4、0.2和0,而12周研究时分别为4.4、0和0。
  • 总体8例患者无出血事件(伴FVIII抑制物6例,不伴FVIII抑制物2例);剂量上调使出血控制欠佳患者的年出血率进一步降低;用于控制出血的凝血因子按需使用减少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Emicizumab (ACE910), a recombinant humanized bispecific monoclonal antibody, provides factor VIII (FVIII) cofactor bridging function to restore hemostasis in people with hemophilia A. In a phase 1 trial involving 18 Japanese patients with severe hemophilia A, once-weekly subcutaneous administration of emicizumab 0.3, 1, or 3 mg/kg (cohorts 1, 2, and 3, respectively) was well tolerated and substantially reduced annualized bleeding rates (ABRs) in the presence or absence of FVIII inhibitors. The current study represents an open-label, long-term extension of the previously reported 12-week phase 1 study, in which 16 of 18 patients continued to receive emicizumab for up to 33.3 months. Long-term emicizumab treatment was well tolerated, with no thromboembolic events reported and no neutralizing antiemicizumab antibodies developing during the course of the study. Plasma concentrations of emicizumab increased in a dose-proportional manner, with activated partial thromboplastin times remaining short. In cohorts 1, 2, and 3, respectively, median ABRs remained low at 1.4, 0.2, and 0 compared with 4.4, 0, and 0 in the 12-week study. Overall, 8 patients experienced no bleeding events (6 patients with and 2 patients without FVIII inhibitors); dose up-titration resulted in further reduction in ABRs in patients with suboptimal bleeding control; and the episodic use of clotting factors to control bleeding was reduced. In conclusion, long-term emicizumab treatment demonstrated a favorable safety profile with encouraging efficacy, irrespective of the presence of FVIII inhibitors, in patients with hemophilia A. This study was registered at www.clinicaltrials.jp as #JapicCTI-132195.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shima M, Hanabusa H, Taki M, et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017. PMID: 29296836. doi:10.1182/bloodadvances.2017006684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。